Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II

Yujing Li; Yunhua Liu; Hanchen Xu; Guanglong Jiang; Kevin Van der Jeught; Yuanzhang Fang; Zhuolong Zhou; Lu Zhang; Michael Frieden; Lifei Wang; Zhenhua Luo; Milan Radovich; Bryan P. Schneider; Yibin Deng; Yunlong Liu; Kun Huang; Bin He; Jin Wang; Xiaoming He; Xinna Zhang; Guang Ji; Xiongbin Lu

doi:10.1038/s41467-018-06811-z

Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II

Yujing Li, Yunhua Liu, Hanchen Xu, Guanglong Jiang, Kevin Van der Jeught, Yuanzhang Fang, Zhuolong Zhou, Lu Zhang, Michael Frieden, Lifei Wang, Zhenhua Luo, Milan Radovich, Bryan P. Schneider, Yibin Deng, Yunlong Liu, Kun Huang, Bin He, Jin Wang, Xiaoming He, Xinna ZhangGuang Ji, Xiongbin Lu

Research output: Contribution to journal › Article

7 Scopus citations

Abstract

Heterozygous deletion of chromosome 17p (17p) is one of the most frequent genomic events in human cancers. Beyond the tumor suppressor TP53, the POLR2A gene encoding the catalytic subunit of RNA polymerase II (RNAP2) is also included in a ~20-megabase deletion region of 17p in 63% of metastatic castration-resistant prostate cancer (CRPC). Using a focused CRISPR-Cas9 screen, we discovered that heterozygous loss of 17p confers a selective dependence of CRPC cells on the ubiquitin E3 ligase Ring-Box 1 (RBX1). RBX1 activates POLR2A by the K63-linked ubiquitination and thus elevates the RNAP2-mediated mRNA synthesis. Combined inhibition of RNAP2 and RBX1 profoundly suppress the growth of CRPC in a synergistic manner, which potentiates the therapeutic effectivity of the RNAP2 inhibitor, α-amanitin-based antibody drug conjugate (ADC). Given the limited therapeutic options for CRPC, our findings identify RBX1 as a potentially therapeutic target for treating human CRPC harboring heterozygous deletion of 17p.

Original language	English (US)
Article number	4394
Journal	Nature Communications
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41467-018-06811-z
State	Published - Dec 1 2018

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
Physics and Astronomy(all)

Access to Document

10.1038/s41467-018-06811-z

Fingerprint Dive into the research topics of 'Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II'. Together they form a unique fingerprint.

Cite this

Li, Y., Liu, Y., Xu, H., Jiang, G., Van der Jeught, K., Fang, Y., Zhou, Z., Zhang, L., Frieden, M., Wang, L., Luo, Z., Radovich, M., Schneider, B. P., Deng, Y., Liu, Y., Huang, K., He, B., Wang, J., He, X., ... Lu, X. (2018). Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. Nature Communications, 9(1), [4394]. https://doi.org/10.1038/s41467-018-06811-z

Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. / Li, Yujing; Liu, Yunhua; Xu, Hanchen; Jiang, Guanglong; Van der Jeught, Kevin; Fang, Yuanzhang; Zhou, Zhuolong; Zhang, Lu; Frieden, Michael; Wang, Lifei; Luo, Zhenhua; Radovich, Milan; Schneider, Bryan P.; Deng, Yibin; Liu, Yunlong; Huang, Kun; He, Bin; Wang, Jin; He, Xiaoming; Zhang, Xinna; Ji, Guang; Lu, Xiongbin.

In: Nature Communications, Vol. 9, No. 1, 4394, 01.12.2018.

Research output: Contribution to journal › Article

Li, Y, Liu, Y, Xu, H, Jiang, G, Van der Jeught, K, Fang, Y, Zhou, Z, Zhang, L, Frieden, M, Wang, L, Luo, Z, Radovich, M, Schneider, BP, Deng, Y, Liu, Y, Huang, K, He, B, Wang, J, He, X, Zhang, X, Ji, G & Lu, X 2018, 'Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II', Nature Communications, vol. 9, no. 1, 4394. https://doi.org/10.1038/s41467-018-06811-z

Li, Yujing ; Liu, Yunhua ; Xu, Hanchen ; Jiang, Guanglong ; Van der Jeught, Kevin ; Fang, Yuanzhang ; Zhou, Zhuolong ; Zhang, Lu ; Frieden, Michael ; Wang, Lifei ; Luo, Zhenhua ; Radovich, Milan ; Schneider, Bryan P. ; Deng, Yibin ; Liu, Yunlong ; Huang, Kun ; He, Bin ; Wang, Jin ; He, Xiaoming ; Zhang, Xinna ; Ji, Guang ; Lu, Xiongbin. / Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. In: Nature Communications. 2018 ; Vol. 9, No. 1.

@article{1bc378c4252f492d85e3f830420f66f6,

title = "Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II",

abstract = "Heterozygous deletion of chromosome 17p (17p) is one of the most frequent genomic events in human cancers. Beyond the tumor suppressor TP53, the POLR2A gene encoding the catalytic subunit of RNA polymerase II (RNAP2) is also included in a ~20-megabase deletion region of 17p in 63% of metastatic castration-resistant prostate cancer (CRPC). Using a focused CRISPR-Cas9 screen, we discovered that heterozygous loss of 17p confers a selective dependence of CRPC cells on the ubiquitin E3 ligase Ring-Box 1 (RBX1). RBX1 activates POLR2A by the K63-linked ubiquitination and thus elevates the RNAP2-mediated mRNA synthesis. Combined inhibition of RNAP2 and RBX1 profoundly suppress the growth of CRPC in a synergistic manner, which potentiates the therapeutic effectivity of the RNAP2 inhibitor, α-amanitin-based antibody drug conjugate (ADC). Given the limited therapeutic options for CRPC, our findings identify RBX1 as a potentially therapeutic target for treating human CRPC harboring heterozygous deletion of 17p.",

author = "Yujing Li and Yunhua Liu and Hanchen Xu and Guanglong Jiang and {Van der Jeught}, Kevin and Yuanzhang Fang and Zhuolong Zhou and Lu Zhang and Michael Frieden and Lifei Wang and Zhenhua Luo and Milan Radovich and Schneider, {Bryan P.} and Yibin Deng and Yunlong Liu and Kun Huang and Bin He and Jin Wang and Xiaoming He and Xinna Zhang and Guang Ji and Xiongbin Lu",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41467-018-06811-z",

language = "English (US)",

volume = "9",

journal = "Nat Commun",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II

AU - Li, Yujing

AU - Liu, Yunhua

AU - Xu, Hanchen

AU - Jiang, Guanglong

AU - Van der Jeught, Kevin

AU - Fang, Yuanzhang

AU - Zhou, Zhuolong

AU - Zhang, Lu

AU - Frieden, Michael

AU - Wang, Lifei

AU - Luo, Zhenhua

AU - Radovich, Milan

AU - Schneider, Bryan P.

AU - Deng, Yibin

AU - Liu, Yunlong

AU - Huang, Kun

AU - He, Bin

AU - Wang, Jin

AU - He, Xiaoming

AU - Zhang, Xinna

AU - Ji, Guang

AU - Lu, Xiongbin

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Heterozygous deletion of chromosome 17p (17p) is one of the most frequent genomic events in human cancers. Beyond the tumor suppressor TP53, the POLR2A gene encoding the catalytic subunit of RNA polymerase II (RNAP2) is also included in a ~20-megabase deletion region of 17p in 63% of metastatic castration-resistant prostate cancer (CRPC). Using a focused CRISPR-Cas9 screen, we discovered that heterozygous loss of 17p confers a selective dependence of CRPC cells on the ubiquitin E3 ligase Ring-Box 1 (RBX1). RBX1 activates POLR2A by the K63-linked ubiquitination and thus elevates the RNAP2-mediated mRNA synthesis. Combined inhibition of RNAP2 and RBX1 profoundly suppress the growth of CRPC in a synergistic manner, which potentiates the therapeutic effectivity of the RNAP2 inhibitor, α-amanitin-based antibody drug conjugate (ADC). Given the limited therapeutic options for CRPC, our findings identify RBX1 as a potentially therapeutic target for treating human CRPC harboring heterozygous deletion of 17p.

AB - Heterozygous deletion of chromosome 17p (17p) is one of the most frequent genomic events in human cancers. Beyond the tumor suppressor TP53, the POLR2A gene encoding the catalytic subunit of RNA polymerase II (RNAP2) is also included in a ~20-megabase deletion region of 17p in 63% of metastatic castration-resistant prostate cancer (CRPC). Using a focused CRISPR-Cas9 screen, we discovered that heterozygous loss of 17p confers a selective dependence of CRPC cells on the ubiquitin E3 ligase Ring-Box 1 (RBX1). RBX1 activates POLR2A by the K63-linked ubiquitination and thus elevates the RNAP2-mediated mRNA synthesis. Combined inhibition of RNAP2 and RBX1 profoundly suppress the growth of CRPC in a synergistic manner, which potentiates the therapeutic effectivity of the RNAP2 inhibitor, α-amanitin-based antibody drug conjugate (ADC). Given the limited therapeutic options for CRPC, our findings identify RBX1 as a potentially therapeutic target for treating human CRPC harboring heterozygous deletion of 17p.

UR - http://www.scopus.com/inward/record.url?scp=85055141917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055141917&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-06811-z

DO - 10.1038/s41467-018-06811-z

M3 - Article

C2 - 30349055

AN - SCOPUS:85055141917

VL - 9

JO - Nat Commun

JF - Nat Commun

SN - 2041-1723

IS - 1

M1 - 4394

ER -